Cutivate is a topical skin-care medication that contains fluticasone as its active ingredient. Fluticasone belongs to the class of synthetic corticosteroids and is formulated as a cream in a tube with 10 g or 20 g strengths. In Hong Kong, Cutivate is a prescription-only product (Rx) and is regulated by the Department of Health under the Pharmaceutical Service. It is used to treat inflammatory skin conditions by reducing redness, swelling, and itching.
Fluticasone is a potent glucocorticoid that binds to intracellular glucocorticoid receptors in the skin. This binding:
Because the drug is applied locally, systemic absorption is minimal, allowing targeted anti-inflammatory effects with a lower risk of systemic side effects compared with oral steroids. The onset of action is typically within a few hours, with maximal effect after several days of consistent use.
Cutivate is approved in Hong Kong for the topical management of the following dermatologic indications:
These indications are based on the drug’s anti-inflammatory and immunosuppressive properties, which help control the chronic inflammation that characterises these skin conditions.
Evidence from peer-reviewed dermatology literature suggests that topical fluticasone may be effective for:
These uses are not approved by the Hong Kong Department of Health. Off-label use requires medical supervision and individualized risk assessment.
If you are taking other medications, especially systemic steroids or immunosuppressants, inform your healthcare provider before starting Cutivate.
This article provides educational information about Cutivate and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Cutivate is a high-potency steroid, so routine facial use is generally discouraged due to the risk of skin atrophy and telangiectasia. If facial application is deemed necessary, a dermatologist will prescribe the shortest possible duration and closely monitor for side effects.
Topical fluticasone can be detected in urine only after extensive application over large body areas. For most athletes, occasional therapeutic use is unlikely to trigger a positive result, but it is advisable to disclose all medications to the relevant sports authority.
The formulation typically contains emulsifiers, preservatives (e.g., phenoxyethanol), and moisturising agents such as glycerin. Exact excipient lists are provided in the product’s package insert.
Yes, but the skin should be gently patted dry before application. Applying to wet skin may dilute the dose and reduce efficacy.
Topical corticosteroids can cross the placenta, especially when used over large areas or for prolonged periods. Pregnant patients should only use Cutivate if the potential benefit outweighs the potential risk, under obstetric guidance.
Fluticasone has a higher receptor affinity and longer skin-residence time, giving it a higher potency classification than many mid-potency steroids such as betamethasone dipropionate.
Store at room temperature (15-30 °C). Do not refrigerate or expose the tube to extreme heat, as this can alter the cream’s consistency.
Concurrent use may increase the risk of local infection because corticosteroids suppress immune responses. If an antifungal is required, alternate the applications (e.g., morning antifungal, evening steroid) or use a combined preparation if approved.
Yes, but keep the tube in its original packaging with the prescription label visible. Some countries may require a copy of the prescribing physician’s note for controlled skin-care products.
The different sizes allow clinicians to match the prescribed amount to the extent and severity of the disease, helping to limit waste and reduce the risk of over-use.
